Telitacicept reduces gMG severity in Phase 2 study
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Marisa Wexler is a senior science writer for Myasthenia Gravis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Muscle weakness and fatigue are hallmark symptoms of myasthenia gravis (MG), an autoimmune disorder. MG symptoms may come and go.| Myasthenia Gravis News
Myasthenia gravis occurs when self-reactive antibodies mistakenly attack the body's immune system, causing muscle weakness and fatigue.| Myasthenia Gravis News
Generalized myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness in different parts of the body.| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
People with gMG with difficulty getting diagnosed or hard-to-manage disease symptoms accrue higher healthcare-related costs, per a study.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News
